Predictive value of a serum tumor biomarkers scoring system for clinical stage II/III rectal cancer with neoadjuvant chemoradiotherapy

Table 4 Multivariate analysis of factors affecting the overall survival

Characteristic	Multivariate analysis
	Model 1		Model 2
	HR (95%CI)	P value	HR (95%CI)	P value
Pre-NCRT CEA (< 3.55/> 3.55)	0.529 (0.232-1.205)	0.130
Pre-NCRT CA19-9 (< 19.01/> 19.01)	0.604 (0.300-1.215)	0.158
Pathological TNM stage (0-I/II-III)	0.373 (0.162-0.859)	0.020	0.363 (0.158-0.837)	0.017
NSTB score (0-1/2)			0.485 (0.251-0.940)	0.032

Model 1: Including pre-neoadjuvant chemoradiotherapy (NCRT) carcinoembryonic antigen (CEA) and cancer antigen 19-9 (CA19-9) into multivariate analysis, not including novel serum tumor biomarker (NSTB) score; Model 2: Including NSTB score into multivariate analysis, not including pre-NCRT CEA and CA19-9. NCRT: Neoadjuvant chemoradiotherapy; CEA: Carcinoembryonic antigen; CA19-9: Cancer antigen 19-9; NSTB: Novel serum tumor biomarker score; TNM: Tumor, node and metastasis.